# severe endocrinologic, oncologic, metabolic and neurologic disorders FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders

> No upcoming FDA catalysts in severe endocrinologic, oncologic, metabolic and neurologic disorders; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 30, 2024 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (December 30, 2024)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253dex991.htm)) |
| July 14, 2025 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (July 14, 2025)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113dex991.htm)) |
| March 25, 2026 | [TAXOL® (paclitaxel) FDA approval](https://sec-api.dev/pdufa/paclitaxel) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed, approved | "Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475dex991.htm)) |

## Drugs

- [Corcept](https://sec-api.dev/pdufa/corcept) (CORT)
- [TAXOL® (paclitaxel)](https://sec-api.dev/pdufa/paclitaxel) (TEVA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "severe endocrinologic, oncologic, metabolic and neurologic disorders FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders

```bibtex
@misc{secapidev_indications_severe_endocrinologic_oncologic_metabolic_and_neurologic_disorders_20261116,
  title        = {severe endocrinologic, oncologic, metabolic and neurologic disorders FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_severe_endocrinologic_oncologic_metabolic_and_neurologic_disorders_20261116","title":"severe endocrinologic, oncologic, metabolic and neurologic disorders FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
